TPX 0005

Drug Profile

TPX 0005

Alternative Names: TPX 0005

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TP Therapeutics
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein pp60(c-src) inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 27 Jun 2017 TPX 0005 receives Orphan Drug status for Non-small cell lung cancer in USA
  • 27 Feb 2017 Phase-I/II clinical trials in Solid tumours in USA (PO) (NCT03093116)
  • 23 Mar 2016 Preclinical trials in Solid tumours in USA (PO) (TP Therapeutics pipeline; May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top